- About Us
- Services & Solutions
- WuXi XDC – Bioconjugation
- News & Media
Offering End-to-End Solutions
Universum, a Swedish-based global employer authority, released data on China’s “Top 20 the most attractive employer for Chinese students in 2021.” WuXi Biologics was awarded “China’s Most Attractive Employer”. We were ranked Top2 in the Pharma & Health category for its outstanding employer brand influence. We were also selected in the Top 19 of Science Majors’ “China’s Most Attractive Employer.”
Since 2006, Universum has regularly conducted surveys of graduates in a number of countries every year, with a rigorous analysis of the results and a ranking of the best employers. The “Most Attractive Employers in the Heart of Chinese Students in 2021” survey, based on the responses of more than 60,000 students from 108 top-notch Chinese universities, received nearly 200,000 evaluations from over 260 employers. The ranking is an annual evaluation of employers’ attractiveness in the recruitment market.
Dr. Chris CHEN, CEO of WuXi Biologics, said: “I am really pleased to be named’ China’s Most Attractive Employer’! This year marks the tenth anniversary of WuXi Biologics. In the past decade, we have created our famous ‘WuXi Biologics Quality’ and ‘WuXi Biologics Speed’. We are known for strong execution and flexibility, winning trust from customers, achieving outstanding achievements, and defining the industry benchmark with ‘WuXi Biologics’. Talented people from all fields are the core strength for us to maintain the leading position in the industry. They are the inexhaustible power for us to develop at a sustainable high speed! Welcome more excellent people to join us, explore the world of biologics together with WuXi Biologics, and help the continuous innovation and development of biologics technology! “
Lily XIONG, head of Global Human Resources, said: “We are very honored to be ‘China’s Most Attractive Employer’, a global employer authority. As the world’s leading biologics discovery, development and production platform, WuXi Biologics has been committed to providing a platform for employees to accelerate their career development by giving them full growth space and support. In the process of ‘empowering global customers and creating great cures’, we also hope that more young and talented people will join us and work with us to realize the ambitious vision of ‘ Every drug can be made and every disease can be treated'”.
The success of the past and the confidence in the future of WuXi Biologics comes from the best talent we have. Every year, WuXi Biologics attracts top young talents to join us. In addition to recruiting the best graduates, WuXi Biologics also focus on talent development through comprehensive talent development programs including overseas assignments. Our aim is to develop graduates into outstanding technical experts, functional experts and management experts.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly one-stop service offering and strong value proposition to its global clients.
As of March 22, 2021, there were a total of 361 integrated projects, including 190 projects in pre-clinical development stage, 137 projects in early-phase (phase I and II) clinical development, 32 projects in late-phase (phase III) development and 2 projects in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore around 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.
WuXi Biologics views Environmental, Social, and Governance (ESG) as an integral component of its ethos and business strategy and has established an ESG committee led by the CEO to increase the efficiency while advancing commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.